The latest price target for Silence Therapeutics (NASDAQ:SLN) was reported by HC Wainwright & Co. on March 7, 2025. The analyst firm set a price target for $75.00 expecting SLN to rise to within 12 months (a possible 2569.04% upside). 24 analyst firms have reported ratings in the last year.

The latest analyst rating for Silence Therapeutics (NASDAQ:SLN) was provided by HC Wainwright & Co., and Silence Therapeutics reiterated their buy rating.

There is no last upgrade for Silence Therapeutics

There is no last downgrade for Silence Therapeutics.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Silence Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Silence Therapeutics was filed on March 7, 2025 so you should expect the next rating to be made available sometime around March 7, 2026.

While ratings are subjective and will change, the latest Silence Therapeutics (SLN) rating was a reiterated with a price target of $75.00 to $75.00. The current price Silence Therapeutics (SLN) is trading at is $2.81, which is out of the analyst’s predicted range.